Patent US5489525A successfully refreshed from Google Patents.
US5489525A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies to prostate cells
Assignee: HEALTH AND HUMAN SERVICES DEPARTMENT OF UNITED STATES GOVERNMENT HEALTH AND HUMAN SERVICES, Secretary of
•
Filing: 1992-10-08
•
Granted: 1996-02-06
•
Expires: 2012-10-08
Abstract
Abstract Monoclonal antibodies are provided which bind to an antigen associated with prostate cells, including prostate cancers. The monoclonal antibodies and recombinant forms thereof are used individually or conjugated radioisotopes to target the compounds to cancerous prostate cells, and thus are useful in a variety of diagnostic procedures.
Inventors
- 👤 Ira H. Pastan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 11:43
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6849; A61K47/6851; A61K47/6861; C07K16/30; C07K16/3038; A61K38/00; C07K2319/00; C07K2319/33; C07K2319/55; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/813
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
9 words
A monoclonal antibody which is the PR1 monoclonal antibody.
Claim 2
Dependent Claim
9 words
A monoclonal antibody which is the PR1 monoclonal antibody.
Claim 3
Dependent Claim
34 words
A monoclonal antibody or binding fragment thereof which competes with monoclonal antibody PR1 for binding to a prostate cell associated antigen and which contains VH and VL complementarity determining regions of monoclonal antibody PR1.
Claim 4
Dependent Claim
34 words
A monoclonal antibody or binding fragment thereof which competes with monoclonal antibody PR1 for binding to a prostate cell associated antigen and which contains VH and VL complementarity determining regions of monoclonal antibody PR1.
Claim 5
Dependent Claim
13 words
The monoclonal antibody of claim 2, in which the Fc region is human.
Claim 6
Dependent Claim
13 words
The monoclonal antibody of claim 3, in which the Fv framework is human.
Claim 7
Dependent Claim
11 words
The monoclonal antibody of claim 2, which is an IgG isotype.
Claim 8
Dependent Claim
29 words
A cell line which secretes a monoclonal antibody which competes with monoclonal antibody PR1 for binding to a prostate cell associated antigen and, which is ATCC No. HB 11145.
Claim 9
Dependent Claim
29 words
A cell line which secretes a monoclonal antibody which competes with monoclonal antibody PR1 for binding to a prostate cell associated antigen and, which is ATCC No. HB 11145.
Claim 10
Independent Claim
73 words
A method for screening for the presence of metastatic prostate cancer in an individual, comprising exposing cells or tissues of an individual to a monoclonal antibody or binding fragment thereof which competes with monoclonal antibody PR1 for binding to a prostate cell associated antigen and which containing VH and VL complementarity determining regions of monoclonal antibody PR1 and detecting the binding of the monoclonal antibody or binding fragment to the cells or tissue.
Claim 11
Independent Claim
73 words
A method for screening for the presence of metastatic prostate cancer in an individual, comprising exposing cells or tissues of an individual to a monoclonal antibody or binding fragment thereof which competes with monoclonal antibody PR1 for binding to a prostate cell associated antigen and which containing VH and VL complementarity determining regions of monoclonal antibody PR1 and detecting the binding of the monoclonal antibody or binding fragment to the cells or tissue.
Claim 12
Dependent Claim
11 words
The method of claim 7, wherein the monoclonal antibody is labeled.
Claim 13
Dependent Claim
15 words
The method of claim 8, wherein the label is a radionuclide, fluorescer, enzyme or chemiluminscer.
Claim 14
Dependent Claim
18 words
The method of claim 7, wherein the cells or tissues are exposed in vivo to the monoclonal antibody.
Claim 15
Dependent Claim
30 words
The method of claim 7, wherein the cells or tissues are obtained from the patient and exposed to the monoclonal antibody in vitro under conditions conducive to immune complex formation.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-02-05 | 1999-08-07 | 2000-02-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-02-05 | 2003-08-07 | 2004-02-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-02-05 | 2007-08-07 | 2008-02-06 | $7700.00 | Window Closed / Lapsed |